Moreau P, Attal M, Hulin C, et al. Phase 3 randomized study of daratumumab + bortezomib/thalidomide/dexamethasone (D-VTD) versus VTD in transplant-eligle newly diagnosed multiple myeloma: part 1 CASSIOPEIA results. 24th Congress of EHA, abstract S145.
Relatie tussen reduced intensity conditioneringsregimes en overleving bij NHL-patiënten
sep 2020 | Lymfoom, Stamceltransplantatie